You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. SBIR Phase I: Reactive Cyclic Induction Marine Diesel Emissions Reduction Monitoring and Delivery System Project

    SBC: STec. Technology, Inc.            Topic: ET

    The broader impact of this Small Business Innovation Research (SBIR) Phase I project is the potential reduction of toxic nitrogen oxides (NOx) and harmful carbon dioxide (CO2) emissions from marine diesel engines. There are approximately 4 million diesel-powered craft in use globally, emitting approximately one billion tons of CO2 and 100 million tons of NOx annually. This project seeks to remove ...

    SBIR Phase I 2023 National Science Foundation
  2. SBIR Phase I:Non-invasive Closed Loop Neuromodulation to Treat Obstructive Sleep Apnea

    SBC: NEUROSOMNICSLLC            Topic: MD

    The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is a non-invasive, externally worn appliance for treating obstructive sleep apnea (OSA), a condition affecting over 88 million Americans (26% of the American adult population).Those impacted by OSA are at risk of serious comorbidities such as diabetes, stroke, and heart disease. Many sufferers ...

    SBIR Phase I 2023 National Science Foundation
  3. SBIR Phase II:Improving farmer safety and grain storage efficiencies via an autonomous grain management and extraction robot

    SBC: GRAIN WEEVIL CORPORATION            Topic: R

    The broader/commercial impact of this Small Business Innovation Research (SBIR) Phase II project includes the development and implementation of a robot for post-harvest grain management with the goal of reducing waste, increasing efficiency, and improving the overall sustainability of the agricultural sector. Post-harvest grain management is a crucial aspect of agriculture; However, it can also be ...

    SBIR Phase II 2023 National Science Foundation
  4. ICU-CARE: An interactive mobile app to enhance the efficiency of daily informal caregiving in the intensive care unit

    SBC: SILICON CURES LLC            Topic: NINR

    PROJECT SUMMARY Actively involving informal caregivers in direct patient care at the bedside in the intensive care unit (ICU) has the potential to improve patient, informal caregiver, and health care system outcomes. Practice guidelines call for the liberal inclusion of informal caregivers as active partners in ICU care, but there is a critical, unmet need to develop tools that effectively operati ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Microscope system for large scale optical imaging of neuronal activity using kilohertz frame rates

    SBC: MICROBRIGHTFIELD, LLC            Topic: 105

    Abstract This project aims to develop the 2P-ActivityScope™, a revolutionary new microscope based on a technological breakthrough called second-generation Scanned Line Angular Projection (SLAP2) two photon laser scanning microscopy that was recently developed by Dr. Kaspar Podgorski (Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA). The game-changing innovation in the 2P-Ac ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. High-throughput functional analysis and clinical relevance of all possible variants of a gene

    SBC: HELIGENICS, INC.            Topic: NHGRI

    Modern pharmaceuticals have greatly improved the quality of life for many patients suffering a variety of illnesses. Unfortunately, among the 17 most commonly prescribed drugs, only 6 are highly effective for most patients, 5 have a modest effect, and 6 show little clinical effect. Worse still, unwanted illness and death from treatment of patients with the incorrect drug or dosage causes over 275, ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Validation and Improvement of ISPRI-HCP: An Innovative Platform for Immunogenicity Risk Assessment of Process-related Protein Impurities

    SBC: EPIVAX, INC.            Topic: NIAID

    ABSTRACT The identification and removal of process-related protein impurities (PRPI) from biologic products is a critical step in drug development. Despite recent improvements in the purification and processing of biologics, the presence of immunogenic PRPI continue to raise concerns about drug safety and efficacy. We propose an innovative approach for assessing immunogenicity risk of PRPI using o ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Point-of-care lateral flow immunoassay for diagnosis of pertussis

    SBC: DXDISCOVERY INC            Topic: NIAID

    Pertussis (Whooping cough) is a highly contagious, airborne disease that is rapidly re-emerging as a serious public health threat in the United States. Despite high vaccine coverage, annual reported cases in the U.S. have been increasing recently, with an average of 25,000 per year from 2010-2019. This is a level unseen since the early 1960s. Diagnosis of pertussis is challenging because its early ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. BEASTS-Novel Biomimetic Liver Platform for Enabling ALD Researchers

    SBC: KESHAVA BIOSCIENCES LLC            Topic: 350

    PROJECT SUMMARY Alcoholic liver disease (ALD) is one of the major causes of morbidity and mortality in the world. Significant challenges remain for developing preventive or curative approaches targeting ALD. No effective treatments for ALD currently exist but for reducing alcohol consumption or liver transplantation. The current paucity of clinically relevant experimental models impedes any effort ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: 100

    Abstract Duchenne Muscular Dystrophy (DMD) is a fatal muscle disease with an incidence of 1 in 5000 males. DMD results from mutations in the gene encoding dystrophin, a 427 kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and laminin in the extracellular matrix. The α7β1 integrin is a transmembrane linkage system in skeletal and card ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government